A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat

Diabetes

Volumn 48, Issue 7, 1999, Pages 1415-1424

  Brown, Kathleen K ^a   Henke, Brad R ^a   Blanchard, Steven G ^a   Cobb, Jeff E ^a   Mook, Robert ^a   Kaldor, Istvan ^a   Kliewer, Steven A ^a   Lehmann, Jurgen M ^a   Lenhard, James M ^a   Harrington, Wallace W ^a   Novak, Paul J ^a   Faison, Walter ^a   Binz, Jane G ^a   Hashim, Mir A ^a   Oliver, William O ^a   Brown, H Roger ^a   Parks, Derek J ^a   Plunket, Kelli D ^a   Tong, Wei Qin ^a   Menius, J Alan ^a   Adkison, Kimberly ^a   Noble, Stewart A ^a   Willson, Timothy M ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS PERFUSION; PRIORITY JOURNAL; RAT;

ANIMALS; BENZOPHENONES; CHROMANS; CLONE CELLS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; OBESITY; PHENOTYPE; RATS; RATS, ZUCKER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TYROSINE;

EID: 0032989265     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.7.1415     Document Type: Article

References (58)

1. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR: Ciglitazone, a new hypoglycemic agent Diabetes 32:830-838, 1983
2. Clark DA, Goldstein SW, Volkmann RA, Eggler JF, Holland GF, Hulin B, Stevenson RW, Kreutter DK, Gibbs EM, Krupp MN, Merrigan P, Kelbaugh PL, Andrews EG, Tickner DL, Suleske RT, Lamphere CH, Rajeckas FJ, Kappeler WH, McDermott RE, Hutson NJ, Johnson RM: Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. J Med Chem 34:319-325, 1991
3. Cantello BBC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurbey PL: [[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37: 3977-3985, 1994
4. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810, 1983
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
6. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky, JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203, 1992
8. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956, 1995
10. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of the thiazolidinediones. J Med Chem 39:665-668, 1996
11. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE: Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 54:801-808, 1997
12. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell 83:835-839, 1995
13. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci U S A 94:4318-4323, 1997
14. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, eicosanoids and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11:779-791, 1997
15. Yu K, Bayona W, Kallen CB, Hardin HP, Ravera CP, McMahon G, Brown M, Lazar MA: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270:23975-23983, 1995
16. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819, 1995
17. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812, 1995
18. Ricote M, Li AC, Willson T, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82, 1998
19. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors a and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410, 1997
20. Schoonjans K, Staels B, Auwerx J: Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37:907-925, 1996
21. Brown PJ, Smith-Oliver TA, Charifson PS, Tomkinson NCO, Fivush AM, Stenbach DD, Wade LE, Orband-Miller, Parks DJ, Blanchard SG, Kliewer SA, Lehmann JM, Willson TM: Identfication of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chem Biol 4:909-918, 1997
22. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137:354-366, 1996
23. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
24. Brun RP, Kim JB, Hu E, Altiok S, Speigelman BM: Adipocyte differentiation: a transcriptional regulatory cascade. Curr Opin Cell Biol 8:826-832, 1996
25. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE: Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest 97:2553-2561, 1996
26. Keller H, Wahli W: Peroxisome proliferator-activated receptors: a link between endocrinology and nutrition? Trends Endocrinol Metab 4:291-296, 1993
27. Wahli W, Martinez E: Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression. FASEB J 5:2243-2249, 1991
28. Lemberger T, Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12:335-363, 1896
29. Desvergne B, Wahli W: PPAR: a key nuclear factor in nutrient/gene interactions. In lnducible Gene Expression, Vol. 1. Baeuerle PA, Ed. Boston, Birkhauser, 1995, p. 142-176
30. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM: PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15:351-357, 1995
31. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard LM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver WR, Parks DJ, Plunkett KD, Szewczyk JR, Willson TM: N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41:5020-5036, 1998
32. Lorenz JJ, Furdon PJ, Taylor JD, Verghese MW, Chandra G, Kost TA, Haneline SA, Roner LA, Gray JG: A cyclic adenosine 3′,5′-monophosphate signal is required for the induction of IL-1β by TNF-α in human monocytes. J Immunol 155:836-844, 1995
33. Hussman M, Lehmann J, Hoffman B, Hermann T, Tzukerman M, Pfahl M: Antagonism between retinoic acid receptors. Mol Cell Biol 11:4097-4103, 1991
34. Nichols JS, Parks DJ, Consler TG, Blanchard SG: Development of a scintillation proximity assay for PPARγ-ligand binding domain. Anal Biochem 257:112-119, 1998
35. Weir GC, Leahy JL, Barras E, Braunstein LP: Characteristics of insulin and glucagon release from the perfused pancreas, intact isolated islets, and dispersed islet cells. Horm Res 24:62-72, 1986
36. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, Bell GI: Evolution of β-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44:1447-1457, 1995
37. Young M, Eckland D, Lettis S, Eastmond R: Establishing the dose-response curve for metabolic control with troglitazone, an insulin action enhancer in type II diabetes patients. Ann Med 30:206-212, 1898
38. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 13:365-370, 1996
39. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 39:701-709, 1996
40. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, The Troglizazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
41. Staels B, Auwerx J: Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Current Pharmaceutical Design 3:1-13, 1997
42. Krey G, Mahfoudi A, Wahli W: Functional interactions of peroxisome proliferator-activated receptor, retinoid-x receptor and Sp1 in the transcriptional regulation of acyl-coenzyme A oxidase promoter. Mol Endocrinol 9:219-231, 1995
43. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM: Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metab Clin Exp 44:976-981, 1995
44. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
45. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 43:1271-1278, 1994
46. Feingold KR, Soued M, Staprans I, Gavin LA, Donahue ME, Huang BJ, Moser AH, Gulli R, Grunfeld C: Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. J Clin Invest 83:1116-1121, 1989
47. Feingold KE, Soued M, Adi S, Staprans I, Shigenaga J, Doerrler W, Moser AH, Grunfeld C: Tumor necrosis factor-increased hepatic very-low-density lipoprotein production and increased serum triglyceride levels in diabetic rats. Diabetes 39:1569-1574, 1990
48. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 91:4854-4858, 1994
49. Peraldi P, Xu M, Spiegelman BM: Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest 100:1863-1869, 1997
50. Rebrin K, Steil GM, Getty L, Bergman RN: Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 44: 1038-1045, 1995
51. Randle PJ, Kerbey AL, Espinal J: Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diab Metab Rev 4:623-638, 1988
52. Prentki M: New insights into pancreatic β-cell metabolic signaling in insulin secretion. Eur J Endocrinol 134:272-286, 1996
53. Newgard C, McGany JD: Metabolic coupling factors in pancreatic β-cell signal transduction. Annu Rev Biochem 64:689-719, 1995
54. Malaisse WJ, Malaisse-Lagae F, Senner A, Pipeleers DG: Determinants of the selective toxicity of alloxan to the pancreatic β-cell. Proc Natl Acad Sci U S A 79:927-930, 1982
55. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 44:863-370, 1995
56. Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334:777-783, 1996
57. Zhou YP, Grill V: Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80:1584-1590, 1995
58. Cavaghan MK, Ehrmann DA, Myrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997